JP5589130B1 - 結晶及び該結晶を含有してなる医薬製剤 - Google Patents

結晶及び該結晶を含有してなる医薬製剤 Download PDF

Info

Publication number
JP5589130B1
JP5589130B1 JP2013185320A JP2013185320A JP5589130B1 JP 5589130 B1 JP5589130 B1 JP 5589130B1 JP 2013185320 A JP2013185320 A JP 2013185320A JP 2013185320 A JP2013185320 A JP 2013185320A JP 5589130 B1 JP5589130 B1 JP 5589130B1
Authority
JP
Japan
Prior art keywords
crystal
luliconazole
present
alcohol
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013185320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015027972A (ja
Inventor
孝明 増田
誠 後藤
善之 宮田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Priority to JP2013185320A priority Critical patent/JP5589130B1/ja
Application granted granted Critical
Publication of JP5589130B1 publication Critical patent/JP5589130B1/ja
Publication of JP2015027972A publication Critical patent/JP2015027972A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013185320A 2012-09-14 2013-09-06 結晶及び該結晶を含有してなる医薬製剤 Active JP5589130B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013185320A JP5589130B1 (ja) 2012-09-14 2013-09-06 結晶及び該結晶を含有してなる医薬製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012202514 2012-09-14
JP2012202514 2012-09-14
JP2013131504 2013-06-24
JP2013131504 2013-06-24
JP2013185320A JP5589130B1 (ja) 2012-09-14 2013-09-06 結晶及び該結晶を含有してなる医薬製剤

Publications (2)

Publication Number Publication Date
JP5589130B1 true JP5589130B1 (ja) 2014-09-10
JP2015027972A JP2015027972A (ja) 2015-02-12

Family

ID=49237577

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013185320A Active JP5589130B1 (ja) 2012-09-14 2013-09-06 結晶及び該結晶を含有してなる医薬製剤

Country Status (7)

Country Link
US (1) US9012484B2 (OSRAM)
EP (1) EP2895165B1 (OSRAM)
JP (1) JP5589130B1 (OSRAM)
CN (1) CN104284662A (OSRAM)
IN (1) IN2015DN02929A (OSRAM)
RU (1) RU2622644C2 (OSRAM)
WO (1) WO2014042231A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409789B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102933201B (zh) 2010-06-11 2015-12-16 宝丽制药股份有限公司 抗真菌药物组合物
JP5460797B1 (ja) 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
EP2895479A1 (en) 2012-09-14 2015-07-22 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5680161B1 (ja) * 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
US10703744B2 (en) 2014-12-12 2020-07-07 Glenmark Life Sciences Limited Process for preparation of luliconazole
JP5951864B1 (ja) * 2015-06-05 2016-07-13 株式会社ポーラファルマ 抗ジアルジア剤
JP2017101009A (ja) 2015-12-04 2017-06-08 株式会社ポーラファルマ 抗アカントアメーバ剤及びその製造法
TR201714882A2 (tr) 2017-10-03 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09100279A (ja) * 1995-07-08 1997-04-15 Nippon Nohyaku Co Ltd 抗真菌剤、その化合物及びその製造方法並びにその使用方法
WO2009031642A1 (ja) * 2007-09-05 2009-03-12 Pola Pharma Inc. 医薬組成物
JP5453559B1 (ja) * 2012-09-14 2014-03-26 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を加工してなる医薬組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
KR100386491B1 (ko) * 1995-07-08 2003-08-21 니혼노야쿠가부시키가이샤 항진균제,이를위한화합물및이의제조방법
JP2002114680A (ja) 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd 抗真菌剤
WO2007102243A1 (ja) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. 外用の医薬組成物
ES2421613T3 (es) 2006-03-08 2013-09-04 Nihon Nohyaku Co Ltd Composición farmacéutica externa
AU2006339841B2 (en) 2006-03-08 2012-08-30 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
JP5345937B2 (ja) 2007-09-05 2013-11-20 株式会社ポーラファルマ 抗真菌組成物
JP5453093B2 (ja) 2007-09-05 2014-03-26 株式会社ポーラファルマ 抗真菌医薬組成物
EP2395839B1 (en) 2009-02-13 2014-05-07 Topica Pharmaceuticals, Inc Anti-fungal formulation
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409789B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102933201B (zh) 2010-06-11 2015-12-16 宝丽制药股份有限公司 抗真菌药物组合物
US8728210B2 (en) 2011-07-07 2014-05-20 Hsueh Yuan Lee Exhaust gas treatment apparatus and method
CN103012385B (zh) * 2012-02-17 2015-07-08 山东威智医药工业有限公司 卢立康唑的晶型及其制备方法
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
JP5460797B1 (ja) 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
IN2015DN02377A (OSRAM) 2012-09-14 2015-09-04 Pola Pharma Inc
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09100279A (ja) * 1995-07-08 1997-04-15 Nippon Nohyaku Co Ltd 抗真菌剤、その化合物及びその製造方法並びにその使用方法
WO2009031642A1 (ja) * 2007-09-05 2009-03-12 Pola Pharma Inc. 医薬組成物
JP5453559B1 (ja) * 2012-09-14 2014-03-26 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を加工してなる医薬組成物

Also Published As

Publication number Publication date
CN104284662A (zh) 2015-01-14
US9012484B2 (en) 2015-04-21
RU2622644C2 (ru) 2017-06-19
EP2895165A1 (en) 2015-07-22
IN2015DN02929A (OSRAM) 2015-09-18
US20140080882A1 (en) 2014-03-20
RU2015113638A (ru) 2016-11-10
WO2014042231A1 (en) 2014-03-20
EP2895165B1 (en) 2016-12-14
JP2015027972A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
JP5589130B1 (ja) 結晶及び該結晶を含有してなる医薬製剤
JP5453559B1 (ja) 晶癖を有する結晶及び該結晶を加工してなる医薬組成物
EP2964641B1 (en) Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
WO2022022434A1 (zh) 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
JP5587488B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5795694B2 (ja) 結晶及び該結晶を含有してなる医薬製剤
JP5680161B1 (ja) 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5795693B2 (ja) 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
KR101981482B1 (ko) 에틸 페룰레이트를 유효성분으로 포함하는 알러지 완화용 조성물
KR20170066196A (ko) 항아칸트아메바제 및 그 제조방법
JP5623671B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5926756B2 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
EP2653159A1 (en) Bromfenac organic salts and preparation method, composition and use thereof
HK40007140A (en) Topical composition comprising terbinafine and preparation method thereof
JP2015113343A (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
HK1223568B (zh) 齐留通乳膏剂型的局部用抗炎症药学组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140728

R150 Certificate of patent or registration of utility model

Ref document number: 5589130

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250